Catherine Smith

16PUBLICATIONS
68CO-AUTHORS
Haematological tumoursMedical molecular engineering of nucleic acids and proteinsMolecular targetsMicrobial geneticsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 13, 2026
Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

|Jul 03, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

|Jun 02, 2026
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.

|Apr 28, 2026
Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.

|Jul 15, 2025
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.

Bogdan Popescu, Matthew F Jones, Madison Piao

|Jun 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Joshua F Zeidner, Tara L Lin, Rina Li Welkie

Pageof 3

Frequent Collaborators

4 joint publications

Joshua F Zeidner

3 joint publications

Tara L Lin

3 joint publications

Alice S Mims

3 joint publications

Elie Traer